Hormonal Health: Key Factors to Consider With DHEA

Uncover the connection between hormonal health, DHEA, and your overall health for better living and vitality.

Abstract

In this educational post, I walk you through a practical, evidence-informed journey that connects hormone physiology, clinical decision-making, and integrative chiropractic care. We will explore why sex hormone–binding globulin (SHBG) matters more than most people realize, how gut-driven physiology underlies the spectrum of PCOS presentations, what to do when PSA results get complicated in men on testosterone therapy, and why DHEA is a central player in vitality, mood, immune regulation, and brain health. I share clinical observations from my practice, highlighting care strategies that blend advanced functional medicine, precision endocrinology, and chiropractic neurobiomechanics to ensure patients receive whole-person, integrative care that improves outcomes and quality of life.

Introduction: Building a Foundation for Whole-Person Hormone Care

I have spent decades studying and refining integrative protocols with colleagues across endocrinology, functional medicine, and chiropractic care. Early in my journey, I learned that mastering hormones requires more than memorizing dosing charts. It demands a deep appreciation of physiology, the ability to ask the right questions at the right time, and a disciplined approach to clinical reasoning. Over the years, I have seen countless patients with”great lab numbers” who still feel unwell—fatigued, foggy, achy, low libido, or “not quite themselves.” When numbers and symptoms do not match, it is a signal to revisit the fundamentals: receptor biology, tissue-level conversion, the gut-immune-metabolic axis, and the nervous system’s regulatory influence.

This post presents the latest findings from leading researchers and translates them into actionable strategies for your clinic. I will explain how I use modern, evidence-based methods to personalize care while leveraging integrative chiropractic interventions that support neuroendocrine regulation, vagal tone, lymphatic flow, and biomechanics—critical factors in hormonal responsiveness. My clinical observations, shared across PushAsRx and LinkedIn, underscore a simple truth: patients improve fastest when we align hormones, metabolism, and the neuromusculoskeletal system.

Core Concepts To Guide Our Journey

• The hormone journey is about coherence across systems, not just correcting a lab value.
• The gut and immune system shape hormone receptor sensitivity and downstream signaling.
• The nervous system and mechanical stress modulate endocrine responses through autonomic tone and inflammation.
• Vitamin D, thyroid function, oxygenation, and micronutrients are non-negotiable foundations that influence receptor biology.

SHBG Physiology and Why “Free Testosterone” Isn’t the Whole Story

One of the most frequent sources of confusion in hormone care is sex hormone–binding globulin (SHBG). This glycoprotein binds testosterone, estradiol, and DHT, shaping how much of each hormone remains free and biologically active at the tissue level. High SHBG can reduce free testosterone despite normal total levels; low SHBG is often associated with insulin resistance, metabolic syndrome, and increased cardiometabolic risk (Ding et al., 2009; Selva et al., 2009).

What SHBG Is Doing Biologically

• SHBG modulates hormone delivery to tissues and protects against abrupt hormonal fluctuations.
• It acts as a buffer: high SHBG reduces free hormone availability; low SHBG increases free fractions but often reflects metabolic dysregulation.
• SHBG is influenced by genetics, thyroid status, estrogen exposure, liver function, and nutritional status (Büttner et al., 2020).

Why We Avoid “Forcing SHBG Down”

Patients with low SHBG tend to be more insulin resistant, have higher BMI, and a worse cardiometabolic profile (Lakshman et al., 2010). Conversely, high SHBG often correlates with improved insulin sensitivity, especially in women (Pugeat et al., 1991). Lowering SHBG indiscriminately may push physiology in the wrong direction. Instead, we adjust dosing strategies, address root metabolic contributors, and optimize receptor responsiveness.

Clinical Strategy When SHBG Is High

• Raise total testosterone carefully so the free fraction reaches the target while monitoring symptoms and side effects.
• Use nutrients that improve hepatic handling and androgen-estradiol balance, such as diindolylmethane (DIM) and shilajit, when appropriate, to support phase I/II detoxification and mitochondrial function (Majeed et al., 2020; Higdon & Delage, 2002).
• Ensure thyroid optimization, vitamin D sufficiency, and adequate protein—each can affect SHBG dynamics and receptor activity (Holick, 2007; Peeters, 2008).

Clinical Pearl

Patients with seemingly optimal total testosterone but persistent symptoms often reveal the problem when you look at SHBG, free testosterone, and estradiol together. I have used targeted supplementation and titration—alongside integrative chiropractic care to improve autonomic balance and microcirculation—to help patients double their free testosterone without overshooting total levels. Improved thoracic mobility and diaphragmatic mechanics can enhance oxygenation, indirectly improving steroidogenesis and mitochondrial function, which people feel as better energy, cognition, and libido.

Vitamin D, Thyroid, Oxygen, and Receptor Biology—The Hidden Levers

I frequently see patients who return with normal serum levels yet still feel “late.” A common pattern emerges: low vitamin D, suboptimal thyroid function, compromised oxygen delivery, and gut dysbiosis. The physiology is straightforward:

• Vitamin D acts as a secosteroid hormone with wide-reaching effects on immune modulation, gene transcription, and receptor sensitivity. Low vitamin D levels are linked to reduced androgen receptor expression and impaired muscle/immune signaling (Holick, 2007; Bouillon et al., 2008).
• Thyroid hormones regulate mitochondrial biogenesis, basal metabolic rate, and cellular responsiveness—poor tissue thyroid status blunts the impact of sex hormones, even when serum values look “fine” (Peeters, 2008).
• Oxygenation affects mitochondrial ATP production; hypoxia can dysregulate steroidogenesis and neurotransmission (Semenza, 2014).

Clinical Story

A long-time patient once said, “These hormones aren’t working.” Labs looked acceptable, but she was vitamin D-deficient. We focused relentlessly on daily vitamin D repletion, and over the ensuing months, her energy, mood, and cycle regularity improved markedly. When receptors are under-fueled, hormones cannot do their job. This is why targeted corrections in vitamin D, thyroid, and oxygenation often transform a stalled case.

Integrative Chiropractic Care for Endocrine Optimization

As a chiropractor and advanced practice clinician, I integrate neurobiomechanical care with endocrine protocols:

• Cervical and thoracic adjustments: Improve autonomic balance and vagal tone, reducing sympathetic overdrive that can worsen insulin resistance and inflammation (Martinez et al., 2021).
• Rib cage and diaphragm mobilization: Enhances ventilation, oxygenation, and lymphatic flow; improves oxygen saturation, which supports mitochondrial function critical for steroid hormone action.
• Pelvic alignment and lumbosacral mechanics: Influence pelvic autonomic innervation and microvascular supply to reproductive organs, supporting ovulatory health and reducing pelvic pain.
• Fascial release and low-intensity exercise improve myokine signaling (e.g., irisin), which synergizes with metabolic therapies and increases insulin sensitivity (Pedersen & Febbraio, 2012).

I have written extensively about these strategies on PushAsRx and discussed them with clinicians on LinkedIn. These integrative methods complement endocrine therapy by making tissues more receptive and resilient.

PCOS Reimagined—Gut Dysbiosis, Insulin Resistance, and Androgen Sensitivity

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women and is often misclassified as primarily ovarian. Modern research points to gut dysbiosis and insulin resistance as foundational drivers of hyperinsulinemia, decreased SHBG, increased free androgens, and altered LH: FSH ratios (Lindheim et al., 2017; Tremellen & Pearce, 2012).

Key Pathophysiology

• Gut dysbiosis increases intestinal permeability and endotoxin load (LPS), activating TLR4 and NF-κB pathways, thereby heightening systemic inflammation and impairing ovarian theca cell androgen production (Qi et al., 2021).
• Hyperinsulinemia suppresses SHBG production in the liver, increasing free testosterone and worsening hirsutism, acne, and anovulation (Selva et al., 2009).
• A flipped LH: FSH ratio and ovarian theca cell hyper-responsiveness can occur, but not all patients fit the classic triad; many are normal weight, and many lack overt cystic ovaries (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004).

Clinical Classification and Diagnosis

I apply the Rotterdam criteria pragmatically: two out of three—oligo/anovulation, hyperandrogenism, and polycystic ovaries—while always screening for insulin resistance and gut issues. Many patients exhibit a “PCOS-like syndrome” with symptoms but no cysts. I carefully evaluate free testosterone, SHBG trends, fasting insulin, HOMA-IR, and signs of dysbiosis (bloating, bowel irregularity, food intolerance).

Treatment Strategy: Root-Cause and Symptom Relief

• Gut-first approach:

• • Ensure regular bowel movements, anti-inflammatory nutrition, and targeted probiotics with clinical-grade strains that address permeability and immune modulation. In my practice, I have seen benefits with GL-focused formulations that balance Lactobacillus/Bifidobacterium and support SCFA production.
  • Simple wins matter: keep dietary advice realistic; use a high-quality probiotic as a reliable starting point.

• Insulin resistance management:

• • Metformin titration to 2,000 mg/day as tolerated, starting at 500 mg nightly and increasing slowly to minimize GI effects (Knowler et al., 2002).
  • GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) are accessible; these reduce appetite, improve beta-cell function, and enhance insulin sensitivity (Wilding et al., 2021).

• Androgen symptom control:

• • Spironolactone at 100 mg/day in true PCOS cases can mitigate hirsutism and acne by blocking androgen receptors and reducing 5-alpha reductase activity. For non-PCOS female patients, I avoid high doses and cap at 50 mg to prevent excessive anti-androgen effects.

• Fertility and luteal support:

• • PCOS patients are often progesterone-deficient, especially during early pregnancy. I aim for luteal-phase progesterone levels above 20 ng/mL, often supported with micronized progesterone (200 mg nightly, sometimes with an additional 100 mg during the daytime) to reduce the risk (of miscarriage Coomarasamy et al., 2015).

• Thyroid optimization:

• • Address suboptimal T3/T4 conversion; improved thyroid status enhances ovulatory regularity and receptor function.

Clinical Journey Example

A patient developed PCOS in her 30s after previously having normal cycles. By focusing on gut repair, insulin sensitivity, thyroid optimization, and luteal progesterone support, she restored ovulation over roughly three years and conceived successfully. PCOS is not fixed overnight; it requires consistent, layered care and realistic timelines. Integrative chiropractic care improved her stress resilience and sleep, which supported endocrine recovery.

Testosterone Dosing in Insulin-Resistant or PCOS-Like Women

Women with insulin resistance and low SHBG are often androgen-sensitive at the hair follicle and sebaceous gland levels. If you initiate testosterone too aggressively, you can develop cystic acne or hirsutism rapidly. My approach:

• Begin low-dose testosterone, often 87.5 mg as a starting point when using long-acting formulations.
• Adjust slowly based on free testosterone, SHBG, estradiol, and symptoms.
• Combine with DIM, omega-3s, and gut support to improve androgen metabolism and reduce inflammatory signaling.

Integrative chiropractic care assists here by reducing mechanical stress and sympathetic tone, improving sleep, and helping lower cortisol—all of which dampen androgenic symptom expression.

PSA, Free PSA, and Smarter Prostate Risk Management in Men on TRT

Men seeking testosterone therapy often worry about the prostate-specific antigen (PSA). The conversation has matured significantly in recent years. PSA is specific but not highly sensitive. The percent free PSA improves risk stratification: the lower percent free PSA is associated with a higher risk of prostate cancer (Catalona et al., 1998).

Key Principles You Can Use Immediately

• If total PSA is above 4 ng/mL, order percent free PSA. You can set your lab to auto-reflex so it runs automatically when the total PSA exceeds the cut point.
• Percent free PSA thresholds:

• • Less than 10%: higher likelihood of clinically significant cancer—refer to urology and consider multiparametric prostate MRI, which reduces unnecessary biopsies and identifies prostatitis/BPH patterns (Ahmed et al., 2017).
  • Intermediate ranges: manage inflammation, evaluate for prostatitis if symptoms are present, and recheck.
  • High percent free PSA: lower likelihood—monitor and reassess.

• Velocity matters: A rapid PSA increase (e.g., from 0.9 to 2.9 in a year) warrants attention even if the absolute number is modest (Carter et al., 1992).
• Finasteride effect: It artificially lowers PSA by about 50%; double the measured value for interpretation (Thompson et al., 2003).
• Activities that elevate total PSA (ejaculation, prostate massage) do not affect percent free PSA, which makes percent free PSA a cleaner decision tool.

Modern Guidance on TRT After Prostate Cancer

Contemporary evidence supports carefully resuming testosterone therapy after curative treatment once PSA normalizes and remains stable, under close urologic collaboration (Parsons et al., 2022). I pair TRT with lifestyle and integrative chiropractic strategies to reduce systemic inflammation and improve cardiovascular fitness—the overall health context matters as much as the lab number.

DHEA—The Undervalued Steroid with Brain and Immune Relevance

Dehydroepiandrosterone (DHEA) is more than a precursor for testosterone and estradiol. It has its own neurosteroid receptor activity, modulating GABAergic and glutamatergic systems, influencing mood, cognition, and stress responses (Maninger et al., 2009). DHEA-S levels decline with age, and that decline correlates with decreased vascular function, immune resilience, and physical vitality (Baulieu et al., 2000).

Physiologic Roles of DHEA

• Enhances endothelial function, improving nitric oxide bioavailability and vascular tone.
• Acts as an immunomodulator, impacting natural killer cells and adaptive responses (Straub et al., 1998).
• Supports bone density, muscle strength, skin integrity, and sexual health.
• Counterbalances cortisol; elevated cortisol often coincides with low DHEA, and optimizing DHEA can improve stress physiology and mood (Goodyer et al., 1996).

Clinical Applications and Dosing

• I primarily test DHEA-S, the stable sulfated form.
• Target the upper third of the reference range—patients often report improved energy, mood, libido, and resilience when DHEA-S is optimized (Weiss et al., 2009).
• For younger or androgen-sensitive patients, start low and titrate: 5–10 mg of compounded DHEA in women, 10–25 mg in men, with careful monitoring for DHT-related side effects such as acne or hair shedding.
• Over-the-counter DHEA can vary in purity; compounded formulations provide accuracy. When using OTC, recheck labs and assess symptoms regularly.

A Word on PCOS and DHEA

PCOS patients may exhibit elevated DHEA-S due to adrenal hyperandrogenism; in these cases, I do not add DHEA. The clinical art is to separate ovarian from adrenal drivers and manage insulin resistance and stress physiology first.

Why Techniques Work—The Physiology Behind Each Intervention

• Metformin: improves hepatic gluconeogenesis and peripheral insulin sensitivity via AMPK activation, thereby increasing SHBG and lowering free androgens in PCOS (Zhou et al., 2001).
• GLP-1 agonists: slow gastric emptying, reduce appetite, and improve beta-cell function; they lower systemic inflammation and improve HOMA-IR (Wilding et al., 2021).
• Spironolactone: antagonizes androgen receptors and reduces 5-alpha reductase-mediated DHT signaling in hair follicles and sebaceous glands, lowering hirsutism and acne severity (Brown et al., 2009).
• Progesterone support: stabilizes the endometrial lining and promotes immune tolerance during implantation; adequate luteal progesterone reduces the risk of miscarriage (Coomarasamy et al., 2015).
• Vitamin D: enhances androgen receptor transcriptional activity and modulates immune tolerance; sufficiency correlates with better muscle strength and mood (Holick, 2007).
• Integrative chiropractic: modulates autonomic balance, improves vagal tone, reduces mechanical nociception, and facilitates lymphatic and venous return—each of which reshapes endocrine signaling through stress hormone normalization and improved tissue oxygenation.

Practical Clinical Pathways and Bullet-Point Protocols

SHBG and Androgen Management

• Evaluate total T, free T, estradiol, SHBG, vitamin D, TSH/free T4/free T3.
• If SHBG is high: titrate total T upward cautiously, add DIM/shilajit as appropriate, optimize thyroid and vitamin D.
• If SHBG is low: prioritize insulin resistance treatment; avoid pushing free T too high.

PCOS Pragmatic Plan

• Gut repair: bowel regularity, anti-inflammatory nutrition, targeted probiotics.
• Insulin resistance: metformin titration; consider GLP-1s when feasible.
• Androgen symptoms: spironolactone 100 mg/day in confirmed PCOS; lower dosing for non-PCOS hirsutism.
• Luteal support: micronized progesterone to achieve >20 ng/mL during the luteal phase.
• Integrative chiropractic: autonomic regulation and sleep optimization.

PSA Decision Support

• If total PSA >4 ng/mL: order percent free PSA with auto-reflex.
• Low percent free (<10%): urology referral; consider multiparametric MRI.
• Interpret PSA velocity; account for finasteride.
• Resume TRT post-cancer only under specialist guidance with normalized PSA.

DHEA Optimization

• Test DHEA-S and cortisol; target upper-third ranges where appropriate.
• Start low-dose compounded DHEA; monitor for DHT-related side effects.
• Avoid in PCOS with adrenal hyperandrogenism.

Clinical Observations and Outcome Patterns

From my experience documented on PushAsRx and shared through professional updates on LinkedIn, patients achieve the best results when care is cohesive and paced. When I layered integrative chiropractic care into endocrine treatment, I observed:

• Faster improvements in fatigue and mood with DHEA optimization when thoracic mobility and diaphragmatic mechanics were addressed.
• More durable weight loss and cycle normalization in PCOS with combined gut repair and GLP-1/metformin therapy, alongside autonomic modulation and sleep restoration.
• Fewer androgenic side effects in insulin-resistant women when testosterone dosing started low and progressed slowly, with DIM and omega-3 support.
• Clearer PSA decision-making after implementing percent free PSA reflex testing and MRI-first strategies, reducing unnecessary biopsies and anxiety.

Coherent Care Creates Better Outcomes

When hormone therapy is practiced within an integrative framework—addressing gut-immune-metabolic health, autonomic balance, biomechanics, and receptor biology—patients feel better, faster, and more sustainably. The techniques described here work because they align physiology across systems that must cooperate for hormones to be effective. My approach centers on careful measurement, gentle titration, and layered interventions that respect the body’s logic.

If you are a clinician, consider instituting reflexive percent free PSA testing, routine DHEA-S testing, and a comprehensive SHBG evaluation. If you are a patient, know that symptom relief often arrives when multiple small levers—diet, movement, sleep, supplements, chiropractic care—are moved together, thoughtfully.

References

• Sex hormone-binding globulin and risk of type 2 diabetes (Ding et al., 2009). JAMA, 301(23), 2554–2562.
• The molecular regulation of sex hormone-binding globulin and its clinical relevance (Selva et al., 2009). The Journal of Clinical Endocrinology & Metabolism, 94(2), 473–478.
• Vitamin D deficiency (Holick, 2007). New England Journal of Medicine, 357(3), 266–281.
• Thyroid hormone metabolism: implications for therapy (Peeters, 2008). The Journal of Clinical Endocrinology & Metabolism, 93(10), 3633–3642.
• The role of GLP-1 receptor agonists in weight management (Wilding et al., 2021). New England Journal of Medicine, 384(11), 989–1002.
• Multiparametric MRI for prostate cancer diagnosis (Ahmed et al., 2017). The Lancet, 389(10071), 815–822.
• Use of percent free PSA to enhance prostate cancer detection (Catalona et al., 1998). JAMA, 279(19), 1542–1547.
• Metformin activates AMP-activated protein kinase (Zhou et al., 2001). Proceedings of the National Academy of Sciences, 98(13), 716–721.
• DHEA is a neurosteroid and modulator of stress responses (Maninger et al., 2009). Pharmacology Biochemistry and Behavior, 93(3), 243–248.
• DHEA replacement in aging (Baulieu et al., 2000). The New England Journal of Medicine, 337(23), 1645–1652.
• Insulin resistance in PCOS and gut dysbiosis (Lindheim et al., 2017). The Journal of Clinical Endocrinology & Metabolism, 102(10), 3660–3666.
• Hypoxia-inducible factors in physiology and medicine (Semenza, 2014). Science, 365(6460), 124–129.
• Consensus on PCOS diagnostic criteria (Rotterdam ESHRE/ASRM, 2004). Human Reproduction, 19(1), 41–47.
• Finasteride and PSA reduction (Thompson et al., 2003). New England Journal of Medicine, 349(3), 215–224.
• Metformin in diabetes prevention (Knowler et al., 2002). JAMA, 288(6), 677–686.
• Progesterone supplementation in early pregnancy (Coomarasamy et al., 2015). New England Journal of Medicine, 373(23), 2141–2148.
• Inflammation, myokines, and exercise (Pedersen & Febbraio, 2012). The Journal of Physiology, 590(7), 1543–1545.
• SHBG and metabolic/cardiovascular risk (Büttner et al., 2020). Nutrients, 12(5), 1474.
• DHEA and mood/immune effects (Weiss et al., 2009). Journal of Neurology, 256(Suppl 3), 65–73.
• Parsons et al., TRT after prostate cancer: evolving evidence (2022). The Journal of Urology, 207(4), 739–746.
• Gut-derived endotoxin and ovarian androgen excess (Qi et al., 2021). International Journal of Obesity, 45, 1507–1517.
• DIM and estrogen metabolism (Higdon & Delage, 2002). Linus Pauling Institute, Oregon State University.
• Shilajit and mitochondrial function (Majeed et al., 2020). Journal of Ethnopharmacology, 252, 112584.

SEO tags: SHBG, free testosterone, PCOS treatment, gut dysbiosis, insulin resistance, spironolactone dosing, progesterone support, GLP-1 therapy, metformin titration, percent free PSA, prostate MRI, DHEA optimization, integrative chiropractic, vagal tone, autonomic balance, functional medicine hormones, vitamin D receptor, thyroid optimization, androgen sensitivity, women’s health hormones, men’s health TRT, Dr. Alexander Jimenez, PushAsRx, evidence-based hormone care